Alpine Immune Sciences Quarterly Income Statements Chart
Quarterly
|
Annual
Alpine Immune Sciences Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 7,032,000 | 30,853,000 | 10,043,000 | 8,593,000 | 9,387,000 | 2,776,000 | 8,367,000 | 5,292,000 | 13,629,000 | 4,530,000 | 8,516,000 | 7,193,000 | 3,204,000 | 5,643,000 | 1,913,000 | 688,000 | 1,091,000 | 884,000 | 289,000 | 567,000 | 390,000 | 315,000 | 128,000 | 128,000 | ||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||
| research and development | 22,457,000 | 22,932,000 | 19,150,000 | 19,241,000 | 19,581,000 | 18,756,000 | 17,589,000 | 17,587,000 | 16,311,000 | 15,362,000 | 18,309,000 | 14,634,000 | 10,437,000 | 9,055,000 | 6,156,000 | 7,096,000 | 4,878,000 | 5,799,000 | 9,532,000 | 10,166,000 | 10,350,000 | 8,931,000 | 10,529,000 | 5,718,000 | 3,792,000 | 3,710,000 | 2,750,000 | 359,000 | 2,758,000 | 5,656,000 | 5,669,000 | 6,424,000 | 5,567,000 | 4,293,000 | 4,279,000 | 4,465,000 |
| general and administrative | 7,271,000 | 6,374,000 | 5,443,000 | 5,007,000 | 5,398,000 | 4,389,000 | 4,610,000 | 4,194,000 | 4,775,000 | 4,544,000 | 3,470,000 | 3,290,000 | 3,256,000 | 3,049,000 | 2,728,000 | 3,344,000 | 1,778,000 | 2,102,000 | 2,467,000 | 2,553,000 | 2,345,000 | 2,514,000 | 1,857,000 | 1,883,000 | 2,108,000 | 1,207,000 | 1,932,000 | 2,592,000 | 2,781,000 | 2,168,000 | 1,879,000 | 2,172,000 | 2,367,000 | 2,337,000 | 1,822,000 | 1,387,000 |
| total operating expenses | 29,728,000 | 29,306,000 | 24,593,000 | 24,248,000 | 24,979,000 | 23,145,000 | 22,199,000 | 21,781,000 | 21,086,000 | 19,906,000 | 21,779,000 | 17,924,000 | 13,693,000 | 12,104,000 | 8,884,000 | 10,440,000 | 6,656,000 | 7,901,000 | 11,999,000 | 12,719,000 | 12,695,000 | 11,445,000 | 12,386,000 | 8,804,000 | 5,900,000 | 4,917,000 | 4,682,000 | |||||||||
| income from operations | -22,696,000 | 1,547,000 | -14,550,000 | -15,655,000 | -15,592,000 | -20,369,000 | -13,832,000 | -16,489,000 | -7,457,000 | -15,376,000 | -13,263,000 | -10,731,000 | -10,489,000 | -6,461,000 | -6,971,000 | -9,752,000 | -5,565,000 | -7,017,000 | -11,710,000 | -12,152,000 | -12,695,000 | -11,445,000 | -12,386,000 | -8,414,000 | -5,585,000 | -4,789,000 | -4,554,000 | -3,815,000 | -9,025,000 | -7,824,000 | -7,548,000 | -8,596,000 | -7,934,000 | -6,630,000 | -6,101,000 | -5,852,000 |
| yoy | 45.56% | -107.59% | 5.19% | -5.06% | 109.09% | 32.47% | 4.29% | 53.66% | -28.91% | 137.98% | 90.26% | 10.04% | 88.48% | -7.92% | -40.47% | -19.75% | -56.16% | -38.69% | -5.46% | 44.43% | 127.31% | 138.99% | 171.98% | 120.55% | -38.12% | -38.79% | -39.67% | -55.62% | 13.75% | 18.01% | 23.72% | 46.89% | ||||
| qoq | -1567.10% | -110.63% | -7.06% | 0.40% | -23.45% | 47.26% | -16.11% | 121.12% | -51.50% | 15.93% | 23.60% | 2.31% | 62.34% | -7.32% | -28.52% | 75.24% | -20.69% | -40.08% | -3.64% | -4.28% | 10.92% | -7.60% | 47.21% | 50.65% | 16.62% | 5.16% | 19.37% | -57.73% | 15.35% | 3.66% | -12.19% | 8.34% | 19.67% | 8.67% | 4.25% | |
| operating margin % | ||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||
| interest income | 4,781,000 | 4,015,000 | 2,891,000 | 2,528,000 | 2,418,000 | 2,165,000 | 664,000 | 314,000 | 145,000 | 93,000 | 52,000 | 51,000 | 63,000 | 43,000 | 11,000 | 44,000 | 152,000 | 105,000 | 109,000 | 82,000 | 115,000 | 117,000 | 96,000 | |||||||||||||
| interest expense | -28,000 | -70,000 | -87,000 | -105,000 | -130,000 | -154,000 | -178,000 | -203,000 | -218,000 | -217,000 | -215,000 | -214,000 | -226,000 | -120,000 | -49,250 | -66,000 | -61,000 | -70,000 | -76,000 | -82,000 | -83,000 | -78,000 | -76,000 | -75,000 | ||||||||||||
| other | -3,000 | 501,000 | -63,000 | -1,000 | -22,000 | |||||||||||||||||||||||||||||||
| net income | -17,918,000 | 5,960,000 | -11,722,000 | -13,156,000 | -13,266,000 | -18,864,000 | -13,273,000 | -18,098,000 | -7,527,000 | -15,167,000 | -13,494,000 | -11,029,000 | -10,643,000 | -6,342,000 | -6,137,000 | -9,928,000 | -5,533,000 | -6,140,000 | -11,475,000 | -11,856,000 | -12,381,000 | -6,563,000 | -6,089,000 | |||||||||||||
| yoy | 35.07% | -131.59% | -11.69% | -27.31% | 76.25% | 24.38% | -1.64% | 64.09% | -29.28% | 139.15% | 119.88% | 11.09% | 92.35% | 3.29% | -46.52% | -16.26% | -55.31% | |||||||||||||||||||
| qoq | -400.64% | -150.84% | -10.90% | -0.83% | -29.68% | 42.12% | -26.66% | 140.44% | -50.37% | 12.40% | 22.35% | 3.63% | 67.82% | 3.34% | -38.18% | 79.43% | -9.89% | -46.49% | -3.21% | -4.24% | 7.78% | |||||||||||||||
| net income margin % | ||||||||||||||||||||||||||||||||||||
| comprehensive income: | ||||||||||||||||||||||||||||||||||||
| unrealized gain on investments | -551,000 | 816,000 | 170,000 | -238,000 | 745,000 | -304,000 | 21,000 | 1,000 | -1,000 | -15,000 | -8,000 | 5,000 | 17,000 | 15,000 | 12,000 | 30,000 | ||||||||||||||||||||
| unrealized loss on foreign currency translation | -109,000 | -5,000 | -31,000 | -4,000 | -14,000 | -15,000 | -113,000 | 11,000 | -7,000 | -14,000 | ||||||||||||||||||||||||||
| comprehensive loss | -18,578,000 | 6,897,000 | -11,612,000 | -13,399,000 | -12,552,000 | -18,316,000 | -13,573,000 | -18,406,000 | -8,315,000 | -15,455,000 | -13,524,000 | -11,017,000 | -10,663,000 | -6,248,000 | -6,123,000 | -9,865,000 | -5,661,000 | -6,137,000 | -11,477,000 | -11,835,000 | -12,380,000 | -7,857,000 | -5,352,000 | -3,700,000 | -8,913,000 | -5,937,000 | -7,451,000 | -8,459,000 | -6,575,000 | -6,074,000 | ||||||
| weighted-average shares used for eps calculation | 64,033,018,000 | 50,000,339,000 | 49,222,344,000 | 48,049,936,000 | 47,568,149,000 | 33,435,280,000 | 31,574,358,000 | 30,324,933,000 | 30,267,472,000 | 25,476,889,000 | 24,724,442,000 | 23,908,516,000 | 23,869,860,000 | 20,826,466,000 | 22,277,146,000 | 18,588,993,000 | 18,587,892,000 | 18,358,864,000 | 18,586,950,000 | 18,576,199,000 | 17,671,918,000 | 13,849,470,000 | 13,851,336,000 | 13,848,974,000 | 13,844,731,000 | 6,481,665 | 10,577,772,000 | |||||||||
| basic and diluted net income per share | -0.28 | 0.15 | -0.24 | -0.27 | -0.28 | -0.5 | -0.42 | -0.6 | -0.25 | -0.53 | -0.55 | -0.46 | -0.45 | -0.25 | -0.28 | -0.53 | -0.3 | -0.33 | -0.62 | -0.64 | -0.7 | |||||||||||||||
| income before taxes | 6,063,000 | -11,722,000 | -13,156,000 | -13,266,000 | -18,316,000 | -13,273,000 | -16,320,000 | -7,523,000 | -15,465,000 | -13,414,000 | -10,898,000 | -6,342,000 | -6,137,000 | -9,934,000 | -6,140,000 | -11,475,000 | -11,856,000 | -12,381,000 | -11,196,000 | -12,139,000 | -8,160,000 | -5,358,000 | -4,522,000 | 2,126,000 | ||||||||||||
| income tax expense | -445,500 | -1,778,000 | -4,000 | 52,000 | -1,000 | -4,000 | ||||||||||||||||||||||||||||||
| unrealized gain on foreign currency translation | 121,000 | -60,000 | 64,000 | 7,000 | -51,000 | -13,000 | -9,000 | 93,000 | 14,000 | 64,000 | 4,000 | |||||||||||||||||||||||||
| income tax benefit | 298,000 | -80,000 | -131,000 | 6,000 | 61,000 | 253,000 | ||||||||||||||||||||||||||||||
| other income | -18,000 | -15,000 | -57,000 | 291,000 | 1,037,000 | 3,250 | 12,000 | |||||||||||||||||||||||||||||
| unrealized loss on investments | 484,000 | -307,000 | -774,000 | -237,000 | -17,000 | -5,000 | 50,000 | -46,000 | -47,000 | -12,000 | ||||||||||||||||||||||||||
| loss on sale of intangible asset | 1,203,000 | |||||||||||||||||||||||||||||||||||
| interest and other income | -1,380,000 | 301,000 | 357,000 | 384,000 | 325,000 | 329,000 | 337,000 | 305,000 | 281,000 | 216,000 | ||||||||||||||||||||||||||
| bargain purchase gain | 62,000 | 6,539,000 | ||||||||||||||||||||||||||||||||||
| basic and diluted net income attributable to common stockholders | -11,135,000 | -12,139,000 | -7,907,000 | -5,306,000 | -4,318,000 | 2,122,000 | ||||||||||||||||||||||||||||||
| comprehensive income | -6,329,500 | -12,109,000 | -869,250 | 2,110,000 | ||||||||||||||||||||||||||||||||
| basic net income per share attributable to common stockholders | -0.458 | -0.88 | -0.218 | 0.2 | ||||||||||||||||||||||||||||||||
| diluted net income per share attributable to common stockholders | -0.458 | -0.88 | -0.218 | 0.18 | ||||||||||||||||||||||||||||||||
| comprehensive loss: | ||||||||||||||||||||||||||||||||||||
| basic and diluted net income per share attributable to common stockholders | -0.57 | -0.38 | ||||||||||||||||||||||||||||||||||
| revenue | ||||||||||||||||||||||||||||||||||||
| restructuring charges | 864,000 | 3,486,000 | ||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -3,710,000 | -8,916,000 | -5,937,500 | -7,433,000 | -8,479,000 | -6,563,000 | -6,089,000 | |||||||||||||||||||||||||||||
| unrealized gains on marketable securities | 10,000 | 3,000 | 500 | -18,000 | 20,000 | |||||||||||||||||||||||||||||||
| weighted-average shares outstanding - basic and diluted | 15,656,000 | 15,644,000 | 15,504,000 | 15,462,000 | 15,462,000 | 9,371,000 | 15,451,000 | 4,159,000 | ||||||||||||||||||||||||||||
| net income per share | -0.24 | -0.57 | -0.5 | -0.48 | -0.55 | -0.51 | -0.21 | -0.39 | -1.41 | |||||||||||||||||||||||||||
| includes stock-based compensation expense | ||||||||||||||||||||||||||||||||||||
| total stock-based compensation expense | 546 | 2,697 | ||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -7,838,000 | -5,852,000 | ||||||||||||||||||||||||||||||||||
| gain on extinguishment of convertible debt as a capital transaction | ||||||||||||||||||||||||||||||||||||
| change in unrealized gains on marketable securities | -12,000 | 15,000 |
We provide you with 20 years income statements for Alpine Immune Sciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Alpine Immune Sciences stock. Explore the full financial landscape of Alpine Immune Sciences stock with our expertly curated income statements.
The information provided in this report about Alpine Immune Sciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.